医院手术量与被认为腹壁游离皮瓣乳房再造结局的关系再探讨
基于2013—2014年美国全国住院患者样本,纳入7145例乳腺癌乳房切除后即刻腹壁游离皮瓣乳房再造患者,评估高手术量医院(年手术量>18例)与结局的关系。调整后高手术量医院患者发生重大并发症和手术部位并发症的风险更低,住院时间更短,但住院费用无差异。
要点
- 高手术量医院(年>18例)患者调整后重大并发症风险更低(OR 0.488,95%CI 0.353-0.675,P<0.001)。
- 高手术量医院手术部位并发症风险也更低(OR 0.678,95%CI 0.519-0.887,P=0.005)。
- 高手术量医院住院时间更短,但住院费用与非高手术量医院无差异。
核心结论
- 与低手术量医院相比,高手术量医院行乳房切除后即刻腹壁游离皮瓣乳房再造似乎与更低的重大并发症发生率和更短的住院时间相关。
- 高手术量医院住院费用并未降低,需进一步研究其如何降低医院成本。
研究设计与样本
- 回顾性队列研究,查询2013—2014年医疗成本与利用项目全国住院患者样本。
- 纳入7145例乳腺癌行乳房切除并即刻腹壁游离皮瓣乳房再造(DIEP或TRAM)的女性患者,分布于473家医院。
- 高手术量医院定义为年手术量≥第90百分位(>18例/年),42.4%的患者在高手术量医院治疗。
- 采用多因素回归和广义线性模型(gamma对数连接)评估高手术量医院相关结局。
主要发现
- 未调整重大并发症发生率在高手术量医院为2.1%,非高手术量医院为4.3%(P<0.001)。
- 未调整手术部位并发症发生率在高手术量医院为3.5%,非高手术量医院为6.1%(P<0.001)。
- 调整临床和医院特征后,高手术量医院重大并发症OR 0.488(95%CI 0.353-0.675,P<0.001),手术部位并发症OR 0.678(95%CI 0.519-0.887,P=0.005)。
- 住院费用在高手术量医院为26822美元,非高手术量医院为26295美元,边际成本528美元(P=0.102)。
- 高手术量医院住院时间4.31天,非高手术量医院4.40天,边际住院时间-0.10天(P=0.005)。
临床怎么用
- 在规划腹壁游离皮瓣乳房再造时,可考虑将患者集中至高年手术量中心以降低并发症风险并缩短住院时间。
- 高手术量中心仍需关注成本控制,因为手术量增加并未带来住院费用下降。
局限性
- 研究为回顾性数据库分析,可能存在未测量混杂因素。
- 仅评估住院期间并发症,缺乏长期结局和患者报告结局。
- 高手术量定义基于样本第90百分位(>18例/年),外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased operative volume has been associated with benefits in patient outcomes for a variety of surgical procedures. In autologous abdominally based breast reconstruction, however, there are few studies assessing the association between procedure volume and patient outcomes. The objectives of this study are to evaluate the associations between abdominal-based free flap breast reconstruction and patient outcomes. METHODS: The 2013-2014 Healthcare Cost and Utilization Project National Inpatient Sample was queried for all female patients with a diagnosis of breast cancer who underwent mastectomy and immediate abdominally based breast reconstruction (deep inferior epigastric perforator or transverse rectus abdominus muscle free flaps). Outcomes included occurrence of major or surgical site in-hospital complications, hospital cost, and length of stay (LOS). High-volume (HV) hospitals were defined as the 90th percentile of annual case volume or higher (>18 cases/y). Multivariate regressions and generalized linear modeling with gamma log-link function were performed to access the outcomes associated with HV hospitals. RESULTS: Overall, 7145 patients at 473 hospitals were studied; of these, 42.4% of patients were treated at HV hospitals. There were significant differences in unadjusted major complications (2.1% vs 4.3%; P < 0.001) and unadjusted surgical site complications (3.5% vs 6.1%; P < 0.001) between HV and non-HV hospitals. After adjustments for clinical and hospital characteristics, patients treated at HV hospitals were less likely to experience a major complication (odds ratio, 0.488; 95% confidence interval, 0.353-0.675; P < 0.001) or surgical site complication (odds ratio, 0.678; 95% confidence interval, 0.519-0.887; P = 0.005). There was no difference in inpatient cost between HV and non-HV hospitals ($26,822 vs $26,295; marginal cost, $528; P = 0.102); however, HV hospitals had a shorter LOS (4.31 vs 4.40 days; marginal LOS, -0.10 days; P = 0.005). CONCLUSIONS: Hospitals that perform a larger volume of immediate abdominal-based breast reconstructions after mastectomy, when compared with those that perform a lower volume of these procedures, seem to have an associated lower rate of major complications and a shorter LOS. However, these same HV centers demonstrate no decrease in costs. Further research is needed to understand how these HV centers can reduce hospital costs.
引用
- Chattha A, Chen AD, Muste J, et al. Revisiting the Relationship Between Hospital Case Volume and Outcomes in Abdominally Based Free Flap Breast Reconstruction. Ann Plast Surg. 2020. PMID: 32102003. doi:10.1097/SAP.0000000000002308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。